The combination of hot melt extrusion (HME) with gummy formulation is a compelling concept that could create a solvent-free, continuous manufacturing process for gummy supplements. HME is established in pharmaceutical manufacturing for producing solid dispersions, and its adaptation to gummy production is an area of active research.
How Hot Melt Extrusion Works
HME feeds raw materials, typically a polymer carrier and active ingredients, into a heated barrel with rotating screws. The heat and mechanical shear melt the polymer into a homogenous mixture, which is then forced through a die to form a continuous ribbon or shape. The process uses no solvents because it relies on melting rather than dissolving the components.
Adapting HME to Gummies
To apply HME to gummy manufacturing, the gelling agents (such as gelatin or pectin), sweeteners, and active ingredients would be fed as dry blends into the extruder. The main challenges, and how they might be handled:
- Temperature Sensitivity: Many gummy ingredients, such as gelatin, degrade under sustained heat. HME barrel temperatures can be controlled from about 30°C up to 250°C, so runs at the low end of that range can protect heat-sensitive ingredients when the polymers are selected to melt there.
- Moisture Management: Traditional gummies need water for hydration and gelation. HME is a dry process, so the melt has to form a gummy texture as it cools. That can mean using thermoplastic gelling agents, or adding a small, precise amount of moisture during extrusion while still avoiding the large water volumes of a cooked batch.
- Continuous Production: HME supports continuous flow by design. Material feeds in one end and finished gummy ribbon or individual units come out the other, which reduces batch-to-batch variation and removes solvent recovery steps.
Potential Benefits
- Solvent-Free: No water or organic solvents are needed, which cuts drying time and energy costs.
- Improved Bioavailability: HME can form amorphous dispersions of poorly soluble actives, which can improve absorption. This is the same mechanism pharmaceutical HME uses to raise the bioavailability of low-solubility drugs.
- Precise Dosing: Continuous extrusion gives tight control over ingredient ratios and active distribution across the run.
- Faster Production: There is no wait for gels to set or dry. Product is ready for packaging once it cools.
Current Limitations
- Texture and Mouthfeel: Gummies made by HME may differ in chewiness and clarity from traditional cooked gummies. Matching the familiar gummy bear texture takes careful work on the polymer blend.
- Heat-Labile Ingredients: Probiotics, some vitamins, and botanical extracts can degrade during extrusion. Lower temperatures, plasticizers, or downstream injection can reduce the loss.
- Equipment Adaptation: Most HME equipment is built for pharmaceutical applications, so specialized dies and cooling systems are needed to form gummy shapes.
- Capital Cost: Pharmaceutical-grade twin-screw extruders are six-figure equipment. Production-scale units commonly run from about $300,000 to $800,000, which favors high-volume runs and can be prohibitive for small and mid-sized producers.
Research on HME Gummies
The idea behind this post is no longer only a thought experiment. In 2026, researchers published a continuous manufacturing platform that couples hot melt extrusion with direct-extrusion 3D printing to make chewable, gummy-like pediatric tablets, in Expert Opinion on Drug Delivery. The study targeted mechanical, dissolution, and sensory properties for pediatric dosage forms.
For a supplement brand, the takeaway is mixed. The publication shows the core concept is technically real: a dry melt can be shaped into gummy-like pieces without the traditional cook-and-set step. It also shows the work remains pharmaceutical dosage-form development, not a commercial gummy line. HME gummies have not yet moved from research into production.
A founder exploring this route should frame it as a joint development project with agreed milestones rather than a drop-in replacement for a stock formula. The promise is real, and it hasn't left the lab.
Our Perspective at KorNutra
At KorNutra, we continually evaluate emerging manufacturing techniques. HME-based gummies are not yet mainstream, but we see potential in the method for clean-label, solvent-free gummies with improved ingredient stability. For now, we treat melt extrusion as an open development project: a brand interested in this route should expect a joint feasibility study and agreed milestones rather than a stock process. Should you wish to explore custom gummy formulations, we welcome the chance to work through the details together.
Combining hot melt extrusion with gummy formulation points toward solvent-free processing, continuous output, and tighter control over active distribution. The technology is still maturing, and it remains an emerging option rather than a standard manufacturing route.